Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.945 USD | +3.70% | +9.89% | +17.80% |
02/05 | Transcript : Arbutus Biopharma Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.80% | 536M | |
-3.35% | 88.91B | |
+2.76% | 41.25B | |
-14.16% | 31.99B | |
+50.51% | 24.73B | |
-14.89% | 15.54B | |
-39.93% | 12.07B | |
-9.08% | 12.05B | |
-14.82% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- ABUS Stock
- News Arbutus Biopharma Corporation
- Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer